1型糖尿病血糖变异性与微血管结局进展在糖尿病控制与并发症试验中的关联
基于糖尿病控制与并发症试验(DCCT),评估每季度7点血糖谱的日内和日间血糖变异性指标与视网膜病变、肾病及心血管自主神经病变发生进展的关联。校正平均血糖后,日内变异性指标均与任何结局无关;仅纵向平均M值与微量白蛋白尿显著相关。总体而言,日内血糖变异性在平均血糖影响之外对微血管并发症的发生无明显作用。
要点
- 校正平均血糖后,日内血糖变异性指标均与视网膜病变、肾病或心血管自主神经病变无关。
- 仅纵向平均M值在校正纵向平均血糖并经Holm法多重检验校正后与微量白蛋白尿显著相关。
- 日内血糖变异性在平均血糖影响之外对微血管并发症的发生无明显作用。
核心结论
- 总体而言,基于每季度血糖谱确定的日内血糖变异性,在平均血糖影响之外对微血管并发症的发生无明显作用。
研究设计与样本
- 糖尿病控制与并发症试验(DCCT)中评估每季度7点血糖谱的日内和日间血糖变异性与视网膜病变、肾病及心血管自主神经病变发生和进展的关联。
- 变异性指标包括日内和随时间更新的均值标准差、血糖波动平均幅度(MAGE)、M值,以及纵向日内、日间和总方差。
- 采用插补法填补预期血糖值中缺失的16.3%。
- 采用Cox比例风险模型将各血糖变异指标作为时间依赖协变量评估其与视网膜病变和肾病风险的关联,采用纵向logistic回归模型对心血管自主神经病变做同样评估。
主要发现
- 校正平均血糖后,日内变异性指标均与任何结局无关。
- 仅纵向平均M值在校正纵向平均血糖并经Holm法多重检验校正后与微量白蛋白尿显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Diabetes Control and Complications Trial (DCCT) demonstrated the beneficial effects of intensive versus conventional therapy on the development and progression of microvascular complications of type 1 diabetes. These beneficial effects were almost completely explained by the difference between groups in the levels of HbA1c, which in turn were associated with the risk of these complications. We assessed the association of glucose variability within and between quarterly 7-point glucose profiles with the development and progression of retinopathy, nephropathy, and cardiovascular autonomic neuropathy during the DCCT. RESEARCH DESIGN AND METHODS: Measures of variability included the within-day and updated mean (over time) of the SD, mean amplitude of glycemic excursions (MAGE), and M-value, and the longitudinal within-day, between-day, and total variances. Imputation methods filled in the 16.3% of expected glucose values that were missing. RESULTS: Cox proportional hazards models assessed the association of each measure of glycemic variation, as a time-dependent covariate, with the risk of retinopathy and nephropathy, and a longitudinal logistic regression model did likewise for cardiovascular autonomic neuropathy. Adjusted for mean blood glucose, no measure of within-day variability was associated with any outcome. Only the longitudinal mean M-value (over time) was significantly associated with microalbuminuria when adjusted for the longitudinal mean blood glucose and corrected for multiple tests using the Holm procedure. CONCLUSIONS: Overall, within-day glycemic variability, as determined from quarterly glucose profiles, does not play an apparent role in the development of microvascular complications beyond the influence of the mean glucose.
引用
- Lachin JM, Bebu I, Bergenstal RM, et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care. 2017. PMID: 28404658. doi:10.2337/dc16-2426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。